Vertical Divider

MeticTouch
First-in-Class Ocular Drug Delivery System

With over than 600 million patients worldwide [1], intravitreal injection is currently one of the most common treatment practice for a wide range of retinal diseases.

Opharmic’s first product, the MeticTouch, is designed with a specific focus on safety, non-invasiveness, and effectiveness in delivering therapeutics for anterior and posterior eye diseases treatment.

[1] World Report on Vision, World Health Organisation, 2019

Clinical Impacts 

Opharmic's MeticTouch system offers non-invasive and effective ocular treatments with targeted drug delivery​.

Highly reducing patient discomfort and fear as well as eliminating risks of procedural and post-operative complications, Opharmic's treatment procedure saves up to 80% of time needed in drug administration in comparison to the conventional eye injection. 

Based on over a decade of research, safety, efficacy, and drug bioavailability of the patented technology behind the system is well-demonstrated in preclinical studies.